40 results about "Bone metastasis" patented technology

The application relates to the field of image processing and discloses a bone metastasis detection and positioning system and method based on SPECT bone imaging. The system extracts and processes multi-scale features of a to-be-detected image through a feature pyramid network to obtain a multi-scale feature map; then extracts metabolic features, morphological features and uptake mode features from the multi-scale feature map through a bone-specific feature model, and gradually fuses the metabolic features, the morphological features and the uptake mode features to obtain a bone-specific enhanced feature map; then extracts and fuses features of the bone-specific enhanced feature map through a mixed feature fusion model to obtain mixed fusion features; finally, the mixed fusion features are subjected to probability reasoning and double-uncertainty quantization processing through a probability reasoning network to determine a bone metastasis detection result, high-precision detection and positioning of bone metastasis lesions are realized, and the problems that existing technologies cannot effectively identify different size lesions and lack global perception ability are effectively solved.

The application discloses a prostate cancer bone metastasis risk prediction diagnosis device and relates to the technical field of prostate cancer diagnosis. The application comprises a diagnosis table, two support rods are symmetrically arranged on one side of the diagnosis table, support plates are arranged on the sides of the two support rods away from each other, an adjusting assembly for adjusting the positions of the support plates is arranged on the support rods, a connecting block is fixed at one end of the diagnosis table, a movable groove is arranged in the connecting block, movable blocks are fixed at the bottom ends of the support rods, and the movable blocks are slidably connected in the movable groove. When rectal digital examination is needed for a patient, the patient is laid on the diagnosis table, the bent parts of the legs of the patient are respectively arranged on the two support plates, the two movable blocks are driven to move away from each other through a driving mechanism, the legs of the patient are bent and separated, and the patient is in a supine position, so that rectal digital examination in a supine position is facilitated.

The invention is suitable for the technical field of medical image processing and artificial intelligence, and provides a urinary system tumor bone metastasis diagnosis method based on deep learning and bone positioning, and the method comprises the steps: collecting and preprocessing multi-modal medical data containing PET / CT images; segmenting a skeleton region by adopting a deep learning model, and realizing focus segmentation in the skeleton region; a lightweight skeleton segmentation network is constructed, and efficient and fine skeleton segmentation is realized through an encoder-decoder structure; pET metabolic features, CT morphological features and texture features are extracted and fused, and a radiomics feature matrix is constructed; carrying out cancer species specificity analysis based on the radiomics characteristic matrix, and constructing an intelligent diagnosis model by utilizing a machine learning algorithm; and finally, outputting a structured report containing the focus position, the type, the cancer classification and the diagnosis confidence. According to the invention, through lightweight network design and multi-modal feature fusion, the efficiency and accuracy of skeleton segmentation and focus diagnosis are significantly improved, and the method is suitable for clinical real-time auxiliary diagnosis.

The invention belongs to the technical field of gene detection, and particularly relates to a prostate cancer bone metastasis diagnostic kit based on gene methylation detection and application of the prostate cancer bone metastasis diagnostic kit. The invention proves that the bone metastasis and non-bone metastasis of the prostate cancer can be effectively distinguished by PCR methylation detection or joint detection based on AKR1B1, RASSF2 and other genes, and a new thought is provided for clinical diagnosis and typing of the bone metastasis of the prostate cancer.

The application discloses a kind of whole body SPECT lung cancer bone imaging data processing method and system, it is related to image processing technical field, comprising: the whole body SPECT lung cancer bone imaging data is input into the improved UNet network after training, local texture feature is extracted by profile wave decomposition module, local texture feature is fused with original image, and the image feature is extracted by inputting fusion feature into UNet encoder;Using the UNet decoder of adding profile wave feature splicing and reconstruction strategy to the extracted image feature, obtains lung cancer bone metastasis lesion area.The application can improve the feature extraction capability of bone imaging lesion segmentation method under low resolution and fuzzy boundary condition.

The invention discloses a drug for combined treatment of breast cancer bone metastasis, the drug comprises two active components, namely a first active component and a second active component, the first active component is Bufalin and its pharmaceutically acceptable salt, prodrug and derivative, and the second active component is RANKL targeted drug; bufalin and a derivative thereof are combined with an RANKL targeted drug for use, the Bufalin and the derivative thereof are synergistically complementary, and the Bufalin is used for regulating and controlling a tumor microenvironment, reducing secretion of high bone metastatic breast cancer cells HMGB1 and inhibiting differentiation of mononuclear / macrophages in bone marrow to osteoclasts, so that occurrence and development of breast cancer bone metastasis are inhibited; the RANKL targeted drug can specifically block an OPG / RANK / RANKL signal channel, inhibit osteoclast activation, reduce bone destruction and block vicious circle of bone metastasis; when the two active ingredients are combined for use, the effect of inhibiting breast cancer bone metastasis is obviously better than that of single use of any active ingredient, the occurrence of breast cancer bone metastasis can be effectively prevented and delayed, the progress of bone metastasis focus is controlled, and the occurrence risk of bone related events is reduced.

The present application relates to a marker IBSP of lung cancer bone metastasis and application thereof. Specifically, the present inventors found that IBSP is highly expressed in both plasma and bone metastasis foci of lung cancer patients, and positively correlates with bone metastasis, thus can be used as a biomarker for detecting and diagnosing bone metastasis. Further studies have proved that the differentiation of macrophages to osteoclasts induced by IBSP is a necessary and sufficient condition for promoting lung cancer bone metastasis, thus IBSP inhibitors can inhibit bone metastasis. In addition, the present inventors first found that IBSP can directly induce the positive differentiation of macrophages to osteoclasts by regulating the Rac1-NFAT signaling pathway, thus inhibiting Rac1 can block the lung cancer bone metastasis induced by IBSP. The present application provides an effective target for diagnosing and treating lung cancer bone metastasis, and provides a new method for the prevention, diagnosis and treatment of bone metastasis.

The invention relates to a tumor bone metastasis prediction system and method based on a bone metastasis specific bone marker. The system comprises a calculation module used for calculating the sensitive weight of each common marker for the same cancer according to the metabolic rate of a plurality of patients for each common marker and the number of the plurality of patients; the compensation module is used for determining a compensation coefficient of each specific marker for the same cancer on the basis of the difference between the detection value of each specific marker of the same patient and historical detection data; the determining module is used for determining a target coupling coefficient of each specific marker according to the relevancy between each specific marker and each common marker of the plurality of patients; and the analysis module is used for carrying out risk analysis according to the sensitive weight, the compensation coefficient, the target coupling coefficient and the target growth speed of each common marker to obtain an analysis result. According to the application, the change synchronism of the common marker and the specific marker can be quantified, the early bone metastasis detection capability is improved, and the misjudgment rate is reduced.

The aqueous pharmaceutical formulation with improved stability comprises denosumab and a poloxamer, and preferably a histidine buffer and / or a sugar or sugar alcohol. The formulation is for use in the treatment or prevention of skeletal-related events associated with osteoporosis, reduced bone mass, multiple myeloma, solid tumor bone metastasis, giant cell tumor of bone, or hypercalcemia.

The application relates to a tumor bone metastasis prediction system and method based on bone metastasis specific bone markers. The system comprises a calculation module, which calculates the sensitive weight of each common marker for the same cancer according to the metabolic speed of each common marker of a plurality of patients and the number of the plurality of patients; a compensation module, which determines the compensation coefficient of each specific marker for the same cancer based on the difference between the detection value of each specific marker of the same patient and historical detection data; a determination module, which determines the target coupling coefficient of each specific marker according to the correlation between each specific marker and each common marker of a plurality of patients; and an analysis module, which performs risk analysis according to the sensitive weight, the compensation coefficient, the target coupling coefficient and the target growth speed of each common marker to obtain an analysis result. The application can quantify the synchronism of the changes of the common markers and the specific markers, improve the early bone metastasis detection capability and reduce the misjudgment rate.

The present application discloses a bone-targeting radiopharmaceutical or imaging agent and a use thereof. The bone-targeting radiopharmaceutical or imaging agent can be used for the treatment or diagnosis of bone diseases, such as bone metastasis from a tumor.

The invention belongs to the technical field of tumor model construction, and discloses a lung adenocarcinoma animal model with high bone metastasis, a cell line and a construction method and application thereof. The lung adenocarcinoma animal model with high bone metastasis is provided through multi-generation in-vivo directional screening, and the construction method is efficient, controllable, high in repeatability, capable of remarkably improving the tumor formation efficiency and rate, capable of being applied to immune healthy mice, low in cost and high in stability. And further extracting tumor cells from the bone metastasis lesion of the animal model to obtain the mouse lung adenocarcinoma cell line with high bone metastasis. The cell line has the advantages of being excellent in bone metastasis performance, stable in phenotype, heritable and the like, can be connected with an existing research system, has universality and economical efficiency, and can efficiently meet the requirement of bone metastasis mechanism research on a high-specificity model. The method can be applied to the fields of construction of tumor animal models or cell lines of bone metastasis, screening or development of lung adenocarcinoma drugs and the like.

The application provides a tumor bone metastasis prediction system and method based on bone metastasis specific bone markers, relates to the technical field of machine learning, and comprises the following steps: an index acquisition module is used for acquiring a plurality of bone marker indexes related to bone metastasis in patient serum obtained by serum detection of a patient; and a bone metastasis prediction module is connected to the index acquisition module, used for inputting each bone marker index into a tumor bone metastasis prediction model trained in advance, so as to predict the early bone metastasis incidence of the patient, thereby providing a reference for clinical diagnosis by doctors. The beneficial effect is that the bone marker content of calcium and phosphorus metabolism regulation indexes, bone formation and bone resorption markers, bone metabolism related hormones and cytokines, and electrolytes in serum is quantitatively detected, and the early bone metastasis incidence is predicted through machine learning, so that the method can be used for early auxiliary diagnosis of tumor bone metastasis, auxiliary evaluation of curative effect in a treatment process and monitoring of metastasis recurrence after treatment, and the detection result can be earlier than clinical symptoms.

The invention discloses a construction method and application of a lung cancer bone metastasis non-human animal model. The construction method comprises the following steps: step 1, constructing a Rosa26 fixed-point human-derived SLC7A7 conditional overexpression mouse model; 2, the R26LSL-slc7a7 homozygous mouse and KrasLSL-G12D / + are subjected to a reaction, and the mouse is subjected to a reaction; the method comprises the following steps: carrying out mating on a Tp53flox / flox mouse, carrying out multiple times of selfing on the obtained heterozygote to obtain a KPS mouse, and delivering an effective dose of Cre recombinase to the lung of the mouse. The invention successfully constructs a genetic engineering animal model capable of inducing three-gene collaborative manipulation, the model can efficiently and stably simulate the whole process of lung adenocarcinoma generation, development and distal bone metastasis, and provides a foundation for deeply exploring the pathogenic mechanism of lung cancer bone metastasis, exploring novel diagnostic markers and developing efficient anti-tumor drugs. And a stable and reliable experimental tool with good clinical correlation is provided.

This invention provides a nucleic acid aptamer that targets and binds to the IGF2BP2 protein and its application, belonging to the field of pharmaceutical technology. This invention is the first to design a highly specific nucleic acid aptamer targeting the RNA recognition protein IGF2BP2, obtaining a nucleic acid aptamer that can target and specifically bind to the IGF2BP2 protein (see SEQ ID No. 1-2). This nucleic acid aptamer can effectively inhibit the activity of tumor cells, tumor stem cells, and breast cancer brain metastases, breast cancer lung metastases, breast cancer liver metastases, breast cancer kidney metastases, and breast cancer bone metastases, providing a new drug component for the treatment of malignant and refractory tumors (especially glioblastoma and distant metastatic breast cancer). Furthermore, it was discovered that modification with N6-methyldeoxyadenosine monophosphate can further enhance the specificity of the nucleic acid aptamer and strengthen its efficacy in inhibiting tumor cell activity.

The present application belongs to the field of biomedicine, and particularly relates to the application of fibroblasts in lung cancer prognosis; and specifically discloses the use of ANXA6 gene in the preparation of a preparation for diagnosing bone metastasis in a subject with lung cancer in vitro and / or for predicting the tendency of forming bone metastasis in a subject with lung cancer in vitro, wherein when overexpression of the ANXA6 gene in CAF is detected, the subject is positively diagnosed with metastasis or has a greater tendency of forming metastasis.

The invention belongs to the technical field of medicine, and discloses an application method of CLIC3 as a serological molecular marker in prediction of lung cancer bone metastasis, CLIC3 is significantly increased in serum of patients with lung cancer bone metastasis, and the total lifetime and non-metastasis lifetime of lung cancer patients with high expression of CLIC3 are significantly shorter than those of patients with low expression. In addition, bone metastasis in a mouse model constructed by CLIC3 high-expression lung cancer cells is remarkably enhanced. Based on detection and analysis of clinical specimens, it is successfully identified that CLIC3 can serve as a brand new serum marker and has a key indication effect in the aspect of early warning of lung cancer bone metastasis. In the research process, multi-dimensional verification is carried out by comprehensively applying a bioinformatics technology, molecular biology detection, a mouse animal model and other methods, and the serum CLIC3 has outstanding potential early warning efficiency and is expected to serve as a novel biological marker with innovativeness, scientificity and clinical application prospects in the early warning category of lung cancer bone metastasis.

The invention discloses application of combination of carboxamide triazole and osimertinib to treatment of non-small cell lung cancer bone metastasis. The administration dosage of carboxamide triazole to adults is 1-10 mg / kg. And the administration dosage of the osimertinib to an adult is 0.05 to 10 mg / kg. In-vivo animal experiments prove that the combined administration group of AZD9291 and CAI HD (40 mg / kg) can significantly inhibit the growth and proliferation (Plt, 0.05) of human lung cancer NCI-H1975-luc xenograft in the tibia of a nude mouse, and the combined administration group of AZD9291 and CAI LD (20 mg / kg) can extremely significantly inhibit the growth and proliferation (Plt, 0.01) of human lung cancer NCI-H1975-luc xenograft in the tibia of the nude mouse.

The application discloses a radionuclide diagnostic and therapeutic agent for targeting CDK19, and belongs to the technical field of biological medicines. Bone metastatic prostate cancer has a poor prognosis in men and is significantly associated with mortality. CDK19 is specifically highly expressed in prostate cancer cells, and a complex formed by CDK19 is involved in the occurrence and development of bone metastasis of prostate cancer, and is a new specific target for treatment and diagnosis of bone metastatic prostate cancer. The radionuclide conjugated drug for targeting CDK19 has a good application prospect in the fields of preparation of diagnostic, staging and therapeutic agents for prostate cancer and medicines.

The invention relates to bionic chitosan hybrid nanogel for treating prostatic cancer osseous metastasis and a preparation method and application thereof, the hybrid nanogel is prepared by the following steps: carrying out a cross-linking reaction on a chitosan monomer and a cross-linking agent glutaraldehyde, introducing ultra-small ferroferric oxide nanoparticles in the reaction process to form the hybrid nanogel, and then loading zoledronic acid to obtain the bionic chitosan hybrid nanogel for treating prostatic cancer osseous metastasis. And further coating a prostate cancer cell membrane. After entering a tumor-bearing nude mouse body through tail vein injection, the pH response type bionic hybrid nanogel prepared by the invention has the advantages of remarkable prostate cancer bone metastasis inhibition and excellent T1 magnetic resonance imaging performance, and has potential clinical application value.

The present application relates to a kind of degradable cationic polymer with bone targeting function and its preparation method and application, specifically, the degradable cationic polymer with bone targeting function provided in the present application can effectively load nucleic acid (such as mRNA, miRNA, DNA), and the encapsulation efficiency is more than 90%, and stable nanoparticles are formed by electrostatic interaction, protect nucleic acid from degradation, while having the characteristics of slowing down particle positive electricity.This carrier shows better stability compared with LNP, supports long-term storage at low temperature.Its bone targeting is clear, promotes the accurate delivery of nucleic acid to bone tissue, enhances the efficacy and reduces side effects, while showing biocompatibility for osteoblasts without toxicity.The application range is wide, covering osteoporosis, osteoarthritis, bone tumor treatment and gene and stem cell therapy.Experiments have verified that the nanoparticles formed by the carrier and eGFP mRNA have high transfection efficiency, and the combination with miRNA effectively inhibits breast cancer bone metastasis, highlighting its therapeutic potential.

The invention relates to the field of medical treatment, in particular to a medicine permeator for a patient with metastatic bone cancer. According to the medicine permeator for the metastatic bone cancer patient, the massage force of an electric massage instrument on the patient can be moderate, the comfort of the patient is improved, medicine mist can permeate into the body of the patient more sufficiently, secondary damage to the patient caused by high-temperature medicine mist is avoided as much as possible, and the absorption effect of the skin of the patient on the medicine mist is better. A medicine permeator for a patient with metastatic bone cancer comprises a barrel, a sliding cover, an air bag and the like. The cylinder body is provided with an air dispersing opening, the air dispersing opening of the cylinder body is connected with a sliding cover in a sliding mode, and the two ends of the cylinder body are fixedly connected with air bags. When the medicine mist permeates into the body of a patient, a medical worker can push the push rod and start the medicine evaporator and the electric massage instrument, the medicine mist can permeate into the body of the patient more sufficiently, meanwhile, the patient can pull the sliding cover, harm caused by the too high temperature of the medicine mist in the barrel is reduced, and the safety of the patient during medicine mist permeation is improved conveniently.

This invention relates to the field of nuclear medicine technology, specifically to a SPECT lung cancer bone metastasis identification method based on multi-bottleneck attention. This method addresses the common problems in current SPECT lung cancer bone metastasis identification processes, such as long diagnosis times, high subjectivity, low consistency, and a high likelihood of missed or misdiagnosed cases when lesion signals are weak. By generating multiple bottleneck tokens captured from different attention patterns and combining local bottlenecks and global average pooling features, the method integrates local key regions with global contextual information, improving classification performance. A pre-trained DINOv3 model is used as the backbone, employing a progressive unfreezing strategy to adapt to specific tasks. It can learn pseudo-three-channel and multi-bottleneck attention during training, ensuring that each bottleneck token always focuses on the most sensitive region for bone metastasis. Gradient backpropagation of multiple bottleneck tokens fine-tunes the channel fusion coefficients, achieving channel-space feedback. This improves recall of scattered small lesions, diagnostic accuracy, and model interpretability without increasing the complexity of Self-Attention.

The invention discloses an I-type collagen cross-linked N-terminal peptide monitoring kit for monitoring tumor bone metastasis, and relates to the field of kits, the I-type collagen cross-linked N-terminal peptide monitoring kit comprises: a solid phase carrier coated with a synthetic NTx peptide; an enzyme labeled anti-NTx monoclonal antibody conjugate; a chemiluminescent substrate solution; the invention relates to a calibrator for quantitatively determining the concentration of I-type collagen cross-linked N-terminal peptide in a urine sample. According to the invention, the multi-gradient calibrator adaptive to the morning urine characteristics of the tumor patient is designed, and the integrated creatinine detection module is integrated to realize synchronous correction, so that the problem of insufficient standardization caused by mismatching of a calibration system and external creatinine detection is effectively solved; meanwhile, the anti-interference capability and the detection stability of the kit in the presence of common endogenous interfering substances of tumor patients such as hemoglobin, bilirubin and chyle are remarkably improved, so that the accuracy of bone resorption degree evaluation and treatment response dynamic monitoring of the bone metastasis patients is comprehensively enhanced.

The application provides the use of a circular non-coding RNA circKCNK2 as a biomarker for predicting bone metastasis of kidney cancer or evaluating the prognosis of kidney cancer. The application also provides a kit for predicting the progression of bone metastasis of renal cell carcinoma or evaluating the prognosis of kidney cancer, which contains primers for detecting the circular non-coding RNA circKCNK2 and detecting the internal reference beta-actin, the upstream primer sequence for detecting the circKCNK2 is shown as SEQ ID NO. 7, the downstream primer sequence for detecting the circKCNK2 is shown as SEQ ID NO. 8, the upstream primer sequence for detecting the beta-actin is shown as SEQ ID NO. 9, and the downstream primer sequence for detecting the beta-actin is shown as SEQ ID NO. 10. The application can understand the bone metastasis event and long-term prognosis of a patient by detecting the expression level of circKCNK2 in the kidney cancer tissue of the patient. It is found in the kidney cancer population that the patients with high expression of circKCNK2 are more likely to have bone metastasis-related PFS events than the patients with low expression of circKCNK2, and the survival is poor.

The invention discloses a bone cement type intramedullary nail device capable of being used for hyperthermic perfusion chemotherapy. The bone cement type intramedullary nail device comprises a main nail, a hyperthermic perfusion injector, a bone cement injector and an aspirator. The main nail is suitable for being implanted into a lesion medullary cavity through a guide needle, a through hollow main nail medullary core is formed in the main nail in the axial direction, an injection opening communicated with the main nail medullary core is formed in the near end of the main nail, and the main nail is suitable for being connected with a hyperthermia perfusion syringe or a bone cement syringe so that chemotherapeutic drugs or bone cement can be injected into the main nail medullary core. A leaking hole communicated with the main nail medullary core is formed in the far end of the main nail, so that chemotherapeutic drugs or bone cement flows into a lesion medullary cavity; and the aspirator is communicated with the diseased medullary cavity through the water outlet screw so as to suck out the chemotherapeutics in the diseased medullary cavity. The bone nail has remarkable beneficial effects in the aspects of mechanical stability, chemotherapy drug hyperthermic perfusion treatment, bone cement filling and fixation enhancement, surgical operation process simplification, main nail structure design optimization and the like, and has a wide application prospect in the field of treatment of limb long tubular bone metastatic cancer.

The invention relates to the technical field of breast cancer prevention and treatment. The invention provides a plant source miRNA (micro Ribonucleic Acid) for preventing and treating breast cancer and application of the plant source miRNA. The plant source miRNA is peu-miR-2916-p3, and the nucleotide sequence of the peu-miR-2916-p3 is as shown in SEQ ID NO. 1. The peu-miR-2916-p3 provided by the invention can resist the progress of breast cancer bone metastasis and has better biological safety, and the clinical treatment of breast cancer bone metastasis is mainly targeted osteoclast at present, but no drug treatment of targeted tumor cells exists, so that the discovery of the invention can provide a new adjuvant therapy for clinical treatment, enhance the clinical treatment effect, and can be used for preparing drugs for treating breast cancer bone metastasis. Meanwhile, plant active ingredients are safer, can be taken for a long time and can be used as a maintenance treatment means in a treatment interval.